Eton Pharmaceuticals, Inc. (ETON) intrinsic value & 10-year financials
Eton Pharmaceuticals, Inc. (ETON) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 109.0% a year to $80.0M, with an average return on invested capital of -296.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $50.31
- Revenue (FY2025)
- $80.0M
- Revenue growth (9-yr CAGR)
- 109.0%
- ROIC (10-yr avg)
- -296.4%
- Free cash flow (FY2025)
- $10.2M
ETON 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $80.0M | -$4.6M | — | $10.2M | -1.1% | -2.4% |
| FY2024 | $39.0M | -$3.8M | — | $943.0K | -6.7% | -13.4% |
| FY2023 | $31.6M | -$936.0K | — | $6.8M | -3.8% | -85.5% |
| FY2022 | $21.3M | -$9.0M | — | $4.8M | -38.9% | -125.0% |
| FY2021 | $21.8M | -$2.0M | — | -$4.7M | -6.8% | -27.4% |
| FY2020 | $39.0K | -$28.0M | — | -$22.4M | -69515.4% | -1384.0% |
| FY2019 | $959.0K | -$18.3M | — | -$19.1M | -1939.6% | -602.0% |
| FY2018 | — | -$12.7M | — | -$8.4M | — | -131.1% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Eton Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Eton Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -50.6% ROIC.
Eton Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Eton Pharmaceuticals, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.